229
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Fibroblast growth factor receptor (FGFR) inhibitors as anticancer agents: 3D-QSAR, molecular docking and dynamics simulation studies of 1, 6-naphthyridines and pyridopyrimidines

, ORCID Icon, , & ORCID Icon
Pages 3591-3606 | Received 29 Dec 2021, Accepted 08 Mar 2022, Published online: 23 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Tian Lu, Tong Li, Meng-Ke Wu, Chi-Chong Zheng, Xue-Mei He, Hai-Liang Zhu, Li Li & Ruo-Jun Man. (2023) Molecular simulations required to target novel and potent inhibitors of cancer invasion. Expert Opinion on Drug Discovery 18:12, pages 1367-1377.
Read now
Achyuta Nagaraj, Sriram Srinivasa Raghavan, Ayyadurai Niraikulam, Namasivayam Gautham & Krishnasamy Gunasekaran. (2023) Sanggenol B, a plant bioactive, as a safer alternative to tackle cancer by antagonising human FGFR. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-12.
Read now

Articles from other publishers (1)

Juni Ekowati, Kholis Amalia Nofianti, Maya Nurwartanti Yunita, Iwan Sahrial Hamid, Fitria Dwiningrum, Darwin Ryan Ramadhan & Ghinalya Chalbi Ananda. (2023) Synthesis, anti-angiogenic activity and prediction toxicity of (E)-3-(3-methoxyphenyl) propenoic acid. Journal of Public Health in Africa.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.